Avermectin B1 toxicity in a herd of Murray Grey cattle

Assessment of Avermectins-Induced Toxicity in Animals

Macrocyclic lactones, particularly the avermectins, have completely revolutionized the approaches aimed at control of parasites. These avermectins are the most widely used anti-parasitic drugs in veterinary field with sales exceeding one billion US dollars annually. However, before clinical usage, their safety evaluation in the animals is a major critical factor that must be considered. Many studies have reported the negative effects of avermectins like ivermectin, abamectin, doramectin, and eprinomectin on the host animals. These harmful effects arise from avermectins targeting GABA and glutamate-gated chloride channels present both in the parasites and the host animals. In this review, various modes of avermectins action along with the negative effects on the host like nephrotoxicity, hepatotoxicity, neurotoxicity, reproductive toxicity, and endocrine disruption were discussed in detail. Furthermore, other important issues like ecotoxicity, drug resistance, and drug residues in milk associated with avermectins usage were also discussed, which need special attention.

Poisoning of calves reared with cows treated with abamectin

The aim of the present study was to describe an outbreak of poisoning by abamectin in calves less than four months of age whose mothers were treated with a pour-on product containing this ingredient. The diagnosis was based on the history, clinical signs, absence of macroscopic and histopathological findings (characteristic of this type of poisoning) and the detection of abamectin in tissues of the animals submitted to necropsy. Based on this report, the recommendation is the use with caution of pour-on formulations containing abamectin on cows having given birth less than four months earlier.

Doramectin toxicity in a group of lions (Panthera leo)

Ten lions (Panthera leo) that were treated with a single injection of doramectin at a dose ranging between 0.2 mg/kg and 0.5 mg/kg showed clinical signs consistent with avermectin toxicity, namely ataxia, hallucinations, and mydriasis. Two subsequently died whereas the other eight lions recovered after 4–5 days with symptomatic therapy. Post-mortem examinations of the two that died showed cyanosis, severe pulmonary oedema, pleural effusion, and pericardial effusion, with histopathology not revealing any abnormalities. In both these lions, doramectin brain and liver tissue concentrations were elevated. Although doramectin is regularly used in wild felids, to date there have been no reports of avermectin toxicity in the literature. This article highlights the potential for doramectin toxicity in this species.

Unique structure and regulation of the nematode detoxification gene regulator, SKN-1: implications to understanding and controlling drug resistance

Nematodes parasitize an alarming number of people and agricultural animals globally and cause debilitating morbidity and mortality. Anthelmintics have been the primary tools used to control parasitic nematodes for the past several decades, but drug resistance is becoming a major obstacle. Xenobiotic detoxification pathways defend against drugs and other foreign chemicals in diverse organisms, and evidence is accumulating that they play a role in mediating resistance to anthelmintics in nematodes. Related antioxidation pathways may also provide filarial parasites with protection against host free-radical-mediated immune responses. Upstream regulatory pathways have received almost no attention in nematode parasites, despite their potential to coregulate multiple detoxification and antioxidation genes. The nuclear eurythroid 2-related factor 2 (NRF2) transcription factor mediates inducible detoxification and antioxidation defenses in mammals, and recent studies have demonstrated that it promotes multidrug resistance in some human tumors. Recent studies in the free-living model nematode, Caenorhabditis elegans, have defined the homologous transcription factor, SKN-1, as a master regulator of detoxification and antioxidation genes. Despite similar functions, SKN-1 and NRF2 have important differences in structure and regulatory pathways. Protein alignment and phylogenetic analyses indicate that these differences are shared among many nematodes, making SKN-1 a candidate for specifically targeting nematode detoxification and antioxidation.

Macrocyclic Lactone Endectocides

The macrocyclic lactone endectocides such as ivermectin, abamectin, selamectin and moxidectin have revolutionized the treatment of parasitic diseases in animals, being active against internal and external parasites. Ivermectin was introduced into veterinary medicine in the 1980s and since that time a number of related compounds have been introduced. In the treatment of internal parasites they complement the use of levamisole and the benzimidazoles, but in recent years they have found utility in treating external insect parasites. These agents show very low levels of toxicity under most circumstances. However, they are neurotoxic particularly in subpopulations of animals with mutations in the MDR1 gene. Toxicity may be also seen during off-label use, possibly because the doses used have been extrapolated from use in other animals. Regardless of these considerations, the macrocyclic lactone endectocides are extremely effective and safe drugs in the treatment of parasitic diseases of animals.

Toxins and adverse drug reactions affecting the equine nervous system

This article provides an overview of the more common toxins and adverse drug reactions, along with more rare toxins and reactions (Table 1), that result in neurologic dysfunction in horses. A wide variety of symptoms, treatments, and outcomes are seen with toxic neurologic disease in horses. An in-depth history and thorough physical examination are needed to determine if a toxin or adverse drug reaction is responsible for the clinical signs. Once a toxin or adverse drug reaction is identified, the specific antidote, if available, and supportive care should be administered promptly.

Control of nematode parasites with agents acting on neuro-musculature systems: lessons for neuropeptide ligand discovery

There are a number of reasons why the development of novel anthelmintics is very necessary. In domestic animals, parasites cause serious loss of production and are a welfare concern. The control of these parasites requires changes in management practices to reduce the spread of infection and the use of therapeutic agents to treat affected animals. The development of vaccines against parasites is desirable but their development so far has been very limited. One notable exception is the vaccination of calves against infection by Dictyocaulus viviparous (lungworm) which has proved to be very effective. In domestic animals, the total market for anti-parasitic agents (both ecto- and endo-parasites) is in excess of a billion U.S. dollars. In humans there are serious problems ofmorbidity and mortality associated with parasite infections. 1.6 billion People throughout the world are infected with ascariasis (Fig. 1A) and/or hookworm. Approximately one-third of the world's population is suffering from the effects of intestinal nematode parasites, causing low growth-rates in infants, ill-thrift, diarrhea and in 2% of cases, loss of life. Despite the huge number of affected individuals, the market for anti-parasitic drugs for humans is not big enough to foster the development of anthelmintics because most infestations that occur are in undeveloped countries that lack the ability to pay for the development of these drugs. The major economic motivator then, is for the development of animal anthelmintics. In both domestic animals and now in humans, there is now a level of resistance to the available anthelmintic compounds. The resistance is either: constitutive, where a given species of parasite has never been sensitive to the compound; or acquired, where the resistance has developed through Darwinian selection fostered by the continued exposure to the anti-parasitic drugs. The continued use of all anthelmintics has and will, continue to increase the level of resistance. Cure rates are now often less than 100% and resistance of parasites to agents acting on the neuromuscular systems is present in a wide range of parasites of animals and humans hosts. In the face of this resistance the development of novel and effective agents is an urgent and imperative need. New drugs which act on the neuromuscular system have an advantage for medication for animals and humans because they have a rapid therapeutic effect within 3 hours of administration. The effects on the neuromuscular system include: spastic paralysis with drugs like levamisole and pyrantel; flaccid paralysis as with piperazine; or disruption of other vital muscular activity as with ivermectin. Figure 1 B and C, illustrates an example ofa spastic effect oflevamisole on infectious L3 larvae of Ostertagia ostertagiae, a parasite of pigs. The effect was produced within minutes of the in vitro application oflevamisole. In this chapter we comment on the properties of existing agents that have been used to control nematode parasites and that have an action on neuromuscular systems. We then draw attention to resistance that has developed to these compounds and comment on their toxicity and spectra of actions. We hope that some of the lessons that the use of these compounds has taught us may to be applied to any novel neuropeptide ligand that may be introduced. Our aim is then is to provide some warning signs for recognized but dangerous obstacles.

Drug delivery systems in domestic animal species

Delivery of biologically active agents to animals is often perceived to be the poor relation of human drug delivery. Yet this field has a long and successful history of species-specific device and formulation development, ranging from simple approaches and devices used in production animals to more sophisticated formulations and approaches for a wide range of species. While several technologies using biodegradable polymers have been successfully marketed in a range of veterinary and human products, the transfer of delivery technologies has not been similarly applied across species. This may be due to a combination of specific technical requirements for use of devices in different species, inter-species pharmacokinetic, pharmacodynamic and physiological differences, and distinct market drivers for drug classes used in companion and food-producing animals. This chapter reviews selected commercialised and research-based parenteral and non-parenteral veterinary drug delivery technologies in selected domestic species. Emphasis is also placed on the impact of endogenous drug transporters on drug distribution characteristics in different species. In vitro models used to investigate carrier-dependent transport are reviewed. Species-specific expression of transporters in several tissues can account for inter-animal or inter-species pharmacokinetic variability, lack of predictability of drug efficacy, and potential drug-drug interactions.

ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics

The emergence of parasites resistant to anthelmintic macrocyclic lactones (MLs) threatens to severely limit current parasite control strategies. Improving the current ML-based chemotherapy to perpetuate the efficacy of this broad-spectrum class of anthelmintics would be advantageous. In recent years it has become evident that the absorption, distribution and elimination of the MLs in hosts and parasites are under the control of multidrug resistance transporters (MDRs) such as P-glycoproteins. Theoretically, the inhibition of these transporters should result in an increase of the drug concentration in the organisms and higher treatment efficiency. This opinion article will discuss the recent findings in this research field and assess the possibilities of this approach being used in the field.

P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin

Salinomycin is a polyether organic anion that is extensively used as a coccidiostatic antibiotic in poultry and commonly fed to ruminant animals to improve feed efficiency. However, salinomycin also causes severe toxicity when accidentally fed to animals in high doses. In addition, humans are highly sensitive to salinomycin and severe toxicity has been reported. Multidrug efflux transporters like P-glycoprotein (P-gp), BCRP, and MRP2 are highly expressed in the intestine and can restrict the oral uptake and tissue penetration of xenobiotics. The purpose of this study was to investigate whether the anionic drug salinomycin is a substrate for one or more of these efflux pumps. Salinomycin was actively transported by human MDR1 P-gp expressed in polarized MDCK-II monolayers but not by the known organic anion transporters human MRP2 and murine Bcrp1. Using P-gp-deficient mice, we found a marked increase in plasma salinomycin concentrations after oral administration and decreased plasma clearance after intravenous administration. Furthermore, absence of P-gp resulted in significantly increased brain penetration. P-gp-deficient mice also displayed clearly increased susceptibility to salinomycin toxicity. Thus far, P-gp was thought to affect mainly hydrophobic, positively charged or neutral drugs in vivo. Our data show that P-gp can also be a major determinant of the pharmacokinetic behavior and toxicity of an organic anionic drug. Variation in P-gp activity might thus directly affect the effective exposure to salinomycin and possibly to other anionic drugs and toxin substrates. Individuals with reduced or absent P-gp activity could therefore be more susceptible to salinomycin toxicity.

Tolerance of therapeutic doses of abamectin and doramectin in Istrian Pramenka sheep

Avermectin endectocides are very effective and safe veterinary drugs, when used at recommended doses. Adverse reactions are described in some species and breeds of animals. In this study, the effects of therapeutic doses of abamectin and doramectin on some haematological and biochemical parameters in Istrian Pramenka sheep are discussed. In the pilot trial, we compared selected haematological and blood biochemical parameters of an experimental sheep flock (40 sheep) with the reference values. Then, two groups of 12 sheep (and their suckling lambs) were chosen from the experimental sheep flock. Each group was subdivided into a control (six animals) and treated (six sheep and their six suckling lambs) groups. We compared haematological and biochemical parameters between control and treated group before subcutaneous administration of abamectin or doramectin (0.2 mg/kg b.w.) and on days 15 and 42 after treatment. In addition, animals were observed for neurological signs. We detected some significant differences (P < 0.05) in some haematological and biochemical parameters between control and treated animals, but none of them appeared to be of clinical importance. No neurological symptoms were observed. Therefore, abamectin and doramectin might be well tolerated in Istrian Pramenka sheep.

Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies

Toxicological studies are conducted on constituents of veterinary medicinal products for a number of reasons. Aside from being a requirement of legislation, they are carried out for predictive purposes in the assessment of user safety or for the determination of consumer safety, for example, in the elaboration of maximum residue limits or tolerances. Alternatively, the results of toxicology studies may be available as they have been generated for registration of the drug for human medicinal purposes. This paper examines if the results of such studies have any predictive value for adverse reactions, which might occur during clinical use in animals. A number of adverse reactions, notably the Type A (toxicology or pharmacology dependent) should be predictable from these laboratory studies. However, as with human pharmaceutical products, they have less utility in predicting Type-B reactions (idiosyncratic in nature).